Currax v. Taro Pharmaceutical: SILENOR® Doxepin Patent Suit Dismissed Without Prejudice
Currax Pharmaceuticals filed a 10-patent infringement action against Taro Pharmaceutical over generic doxepin hydrochloride tablets (3 mg and 6 mg) in the Southern District of New York. The case was voluntarily dismissed without prejudice after 161 days — revealed in the filing to be a protective suit, with the primary action proceeding in the District of New Jersey.
A protective filing that served its purpose: jurisdiction secured in New Jersey
On July 2, 2024, Currax Pharmaceuticals LLC filed a patent infringement complaint in the U.S. District Court for the Southern District of New York against Taro Pharmaceutical Industries Ltd., Taro Pharmaceuticals Inc., and Taro Pharmaceuticals U.S.A., Inc. The complaint asserted ten patents covering SILENOR® (doxepin hydrochloride) tablets — a prescription sleep aid available in 3 mg and 6 mg oral dosage strengths — targeting Taro’s corresponding generic tablet products.
On December 9, 2024, Currax voluntarily dismissed the action without prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i), with each party bearing its own fees and costs. Critically, the filing disclosed that this S.D.N.Y. action was filed as a protective suit, commenced the day after Currax initiated a parallel infringement action asserting the same patents in the District of New Jersey (C.A. No. 1:24-cv-07746). Taro’s consent to personal jurisdiction and venue in New Jersey rendered the New York action redundant.
The 161-day duration reflects only the time needed to confirm Taro’s consent to New Jersey jurisdiction — no substantive litigation activity occurred, and Taro was never served in the S.D.N.Y. proceeding. The public record does not reveal whether any licensing discussions occurred or whether Taro contested validity of any of the ten asserted patents. The operative dispute is now concentrated in the District of New Jersey, where the same patents and products remain at issue.
Filing to Voluntary dismissal in 161 days
161 days — resolved before any service or answer was filed
Voluntarily dismissed: what this S.D.N.Y. exit means for both parties
Rule 41(a)(1)(A)(i): dismissal before service of answer
Under Fed. R. Civ. P. 41(a)(1)(A)(i), a plaintiff may dismiss without a court order before the defendant has served an answer or a motion for summary judgment. Because Taro was never served in this action, Currax could dismiss as of right. This mechanism leaves the merits entirely unresolved — no judgment, no claim construction, no validity ruling attaches.
Pre-service voluntary dismissalDismissed without prejudice: claims survive, venue shifts
The filing expressly states dismissal is without prejudice, meaning Currax retains the right to refile on the same patents and products. Importantly, the same claims are already active in the District of New Jersey (C.A. No. 1:24-cv-07746). The S.D.N.Y. dismissal is a jurisdictional housekeeping step, not a concession on the merits. No inference of weakness on any of the ten asserted patents should be drawn from this filing.
Claims preserved — NJ action liveTaro consented to NJ jurisdiction — tactical concession or pragmatic choice?
By consenting to personal jurisdiction and venue in the District of New Jersey, Taro enabled the S.D.N.Y. dismissal but did not avoid the underlying infringement dispute. Taro was never served in New York and filed no responsive pleading, so no preclusive effect runs in its favour from this dismissal. The full 10-patent portfolio challenge now proceeds in New Jersey on the same footing.
No preclusive benefit for TaroTen-patent ANDA battle consolidates in a single forum
Consolidation of this dispute in the District of New Jersey is commercially significant for the doxepin generic market. With 10 patents in suit covering SILENOR® formulations across multiple application families, the New Jersey action likely triggers Hatch-Waxman 30-month stay considerations. Generic entry timing for Taro’s 3 mg and 6 mg doxepin tablets will depend on the NJ court’s claim construction and validity rulings.
Generic entry timeline at stake in NJFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Currax Pharmaceuticals, LLC | Company | Specialty pharma company — holder of 10 patents covering SILENOR® doxepin hydrochloride tabletsSearch in Eureka ↗ |
| Defendant | Taro Pharmaceutical Industries Limited | Company | Generic pharmaceutical manufacturer and U.S. affiliates targeting the doxepin tablet marketSearch in Eureka ↗ |
| Co-Defendant | Taro Pharmaceuticals U.S.A., Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Taro Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Zachary L. Garrett | Attorney | Counsel for Currax Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Venable LLP | Law Firm | Representing Currax Pharmaceuticals, LLCSearch in Eureka ↗ |
| Presiding judge | Judge Cathy Seibel | Judge | New York Southern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice is explicit that this action was a protective filing, commenced to preserve jurisdictional options while the primary action was established in New Jersey. Because Taro was never served and filed no responsive pleading, the dismissal under Rule 41(a)(1)(A)(i) was as of right — no court order was required. The without-prejudice designation means no claim preclusion or issue preclusion attaches for either party. All ten asserted patents remain live in the New Jersey proceeding, and the merits of infringement and validity are entirely unresolved by this filing.
US9107898B2 and 9 further patents — SILENOR® doxepin hydrochloride tablet portfolio
The ten asserted patents — spanning application filings from 2007 (US11/781165) through 2020 (US16/876492) — collectively cover the SILENOR® product, a low-dose doxepin hydrochloride tablet indicated for sleep-maintenance insomnia. The portfolio appears to encompass formulation claims, method-of-use claims, and dosage regimen claims across 3 mg and 6 mg strengths, representing a layered exclusivity strategy typical of branded specialty pharma products defending against generic ANDA entry.
For the doxepin generic market, this portfolio depth creates substantial freedom-to-operate complexity. A generic entrant cannot simply design around a single patent — Taro must contend with claims filed across more than a decade of prosecution, potentially covering different aspects of the same product. This multi-patent approach is consistent with branded pharma strategies designed to extend market exclusivity beyond any single patent’s expiry and to maximise the litigation and IPR burden on generic challengers.
Should your doxepin tablet product be assessed against these 10 patents?
Any company developing or commercialising generic doxepin hydrochloride tablets in 3 mg or 6 mg oral dosage forms — or formulating low-dose tricyclic antidepressant compositions for sleep indications — should conduct a formal FTO analysis against Currax’s SILENOR® patent portfolio. With ten patents spanning formulation, dosing, and method-of-use claims, the risk surface is broader than typical single-patent ANDA disputes.
PatSnap Eureka’s FTO Search Agent can map each of the ten asserted patents against your product’s formulation and administration characteristics, identify expired claims, flag prosecution history estoppel, and surface relevant prior art that may support invalidity arguments. For teams monitoring the New Jersey action, Eureka’s litigation tracking tools provide real-time docket alerts and claim construction analysis as the case develops.
Run a freedom-to-operate analysis on US9107898B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent infringement cases: doxepin and specialty pharma tablet disputes
Explore comparable Hatch-Waxman patent infringement actions involving specialty pharma tablet formulations and multi-patent portfolios litigated in federal district courts.
What this case signals for the specialty pharma ANDA IP landscape
Protective parallel filings are a recognised ANDA litigation tactic — this case illustrates the mechanics and the jurisdictional leverage they create.
Protective filings are leverage tools, not litigation dead-ends
Currax’s S.D.N.Y. filing was never intended to proceed to trial. Filed one day after the primary New Jersey action, it gave Currax jurisdictional leverage to secure Taro’s consent to the preferred forum. IP teams facing generic ANDA challenges should assess whether parallel protective filings strengthen their venue position before serving the primary complaint.
Ten-patent portfolios in ANDA suits raise the cost of generic entry significantly
Asserting 10 patents across multiple application families — as Currax has done here — substantially increases the litigation cost and complexity for a generic challenger. Each patent requires separate validity and infringement analysis. For Taro, this means prolonged uncertainty over doxepin tablet launch timing and elevated litigation spend, even before any claim construction hearing.
Currax v Taro — key questions answered
Currax disclosed in its dismissal notice that the S.D.N.Y. action was a protective filing, commenced one day after the primary New Jersey infringement action (C.A. No. 1:24-cv-07746, D.N.J.) asserting the same patents. Once Taro consented to personal jurisdiction and venue in New Jersey, the New York case became redundant and was dismissed without prejudice under Rule 41(a)(1)(A)(i).
Currax asserted ten patents: US9107898B2, US9486437B2, US10653662B2, US9861607B2, US8513299B2, US10238620B2, US7915307B2, US10653660B2, US11110074B2, and US9572814B2. These patents cover SILENOR® doxepin hydrochloride tablets (3 mg and 6 mg) and span formulation, dosage, and method-of-use claims filed between 2007 and 2020.
No. A voluntary dismissal without prejudice under Rule 41(a)(1)(A)(i) does not adjudicate the merits and carries no claim preclusion or issue preclusion effect. All ten asserted patents and the infringement allegations against Taro’s generic doxepin tablets remain live in the District of New Jersey proceeding (C.A. No. 1:24-cv-07746).
Taro’s consent to personal jurisdiction and venue in the District of New Jersey resolved the jurisdictional uncertainty that prompted Currax’s protective New York filing. It consolidates the entire SILENOR® patent dispute — all ten patents, both 3 mg and 6 mg products — in a single forum, streamlining the litigation and potentially triggering Hatch-Waxman 30-month stay implications for Taro’s ANDA approval timeline.
No. The dismissal notice expressly states that Taro was not served with the summons or complaint in the S.D.N.Y. action and had not filed an answer or otherwise moved. This is consistent with the protective-filing strategy: the S.D.N.Y. action existed solely to preserve Currax’s jurisdictional options and was terminated once its purpose was achieved.
PatSnap Eureka searches patents and litigation data to answer instantly.